Seaward Management Limited Partnership continued to hold its stake in Hologic Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,671 shares of the company’s stock at the end of the second quarter. Seaward Management Limited Partnership’s holdings in Hologic were worth $473,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the stock. Norges Bank bought a new position in shares of Hologic during the fourth quarter valued at $98,031,000. State Street Corp boosted its stake in Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock worth $355,210,000 after buying an additional 2,150,544 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its stake in Hologic by 276.7% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,818,296 shares of the company’s stock worth $62,913,000 after buying an additional 1,335,551 shares during the last quarter. Panagora Asset Management Inc. boosted its stake in Hologic by 247.3% in the first quarter. Panagora Asset Management Inc. now owns 1,682,853 shares of the company’s stock worth $58,058,000 after buying an additional 1,198,338 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock worth $80,187,000 after buying an additional 819,646 shares during the last quarter. 94.51% of the stock is owned by institutional investors and hedge funds.
Hologic Inc. (NASDAQ:HOLX) traded up 0.65% during mid-day trading on Thursday, reaching $38.78. The company had a trading volume of 1,315,963 shares. The firm has a 50-day moving average of $38.36 and a 200 day moving average of $35.88. The company has a market capitalization of $10.76 billion, a PE ratio of 42.76 and a beta of 1.03. Hologic Inc. has a 1-year low of $31.84 and a 1-year high of $41.66.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The company had revenue of $717.40 million for the quarter, compared to the consensus estimate of $703.66 million. During the same quarter in the prior year, the company earned $0.43 earnings per share. Hologic’s revenue was up 3.4% on a year-over-year basis. On average, analysts predict that Hologic Inc. will post $1.94 earnings per share for the current fiscal year.
A number of research firms have recently commented on HOLX. RBC Capital Markets reiterated a “sector perform” rating and set a $39.00 target price (up from $37.00) on shares of Hologic in a research note on Monday, August 1st. Piper Jaffray Cos. set a $44.00 target price on Hologic and gave the stock a “hold” rating in a research note on Sunday, August 28th. Zacks Investment Research cut Hologic from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Barclays PLC reiterated an “equal weight” rating and set a $42.00 target price on shares of Hologic in a research note on Sunday, July 31st. Finally, Royal Bank Of Canada lifted their target price on Hologic from $37.00 to $39.00 and gave the stock a “sector perform” rating in a research note on Monday, August 1st. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $42.35.
In other Hologic news, Director Nancy Leaming sold 8,179 shares of the stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the transaction, the director now owns 67,140 shares of the company’s stock, valued at $2,484,180. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.84% of the stock is owned by company insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.